论文部分内容阅读
舒巴克坦和YTR830H是许多β-内酰胺酶的有效抑制剂,它们与青霉素类和头孢菌素类联合,扩大了这些抗生素对涉及产生β-内酰胺酶菌类的抗菌谱。然而这类β-内酞胺酶抑制剂受本身抗菌活性弱的限制。曾报道克拉维酸和舒巴克坦抗乙酸钙不动杆菌体外活性比β-内酰胺更显著,但尚未报告β-内酰胺酶抑制剂抗乙酸钙不动杆菌的体内活性。本研究旨在评价舒巴克坦和YTR830H抗这类临床分离菌的体内外活性。
Shybactam and YTR830H are potent inhibitors of many beta-lactamase enzymes that, in combination with penicillins and cephalosporins, have expanded the antibacterial spectrum of these antibiotics for the production of beta-lactamase-producing bacteria. However, these β-lactamase inhibitors are limited by their weak antibacterial activity. It has been reported that clavulanic acid and sulbactam are more potent against β-lactam than β-lactam in vitro activity but β-lactamase inhibitors against Acinetobacter calcoaceticus have not been reported in vivo. The aim of this study was to evaluate the in vitro and in vivo activity of both sulbactam and YTR830H against such clinical isolates.